Global ETD Search

Search theses and dissertations gathered from participating repositories worldwide. Every result links back to the library that holds it. No account is needed.

Results

Showing 1 to 16 of 16 for “"Rucaparib"”.

  1. Copper-mediated radiosynthesis of 18F- and 123I-radiolabelled PARP inhibitors

    … consisting the development of 18F-radiolabelled rucaparib for positron emission tomography (PET) application in cancer diagnosis and development of 123I-radiolabelled rucaparib and olaparib analogues as potential theragnostic agents for Auger therapy.</p> <p><strong>Chapter I</strong> presents a …

    oxford Repository record for Copper-mediated radiosynthesis of 18F- and 123I-radiolabelled PARP inhibitors (opens in a new tab)

  2. In-depth bioinformatics analysis of the phosphoproteome of triple negative breast cancer treated with a tumor selective NQO1 bioactivatable drug

    … breast cancer cells compared to PARP inhibitor Rucaparib. From this proteomics study, large changes in phosphorylation are observed in utilizing a combination therapy with low dose of IB-DNQ and PARP inhibitor Rucaparib. Protein phosphorylation events within the transcription machinery and DNA …

    iupui Repository record for In-depth bioinformatics analysis of the phosphoproteome of triple negative breast cancer treated with a tumor selective NQO1 bioactivatable drug (opens in a new tab)

  3. Characterisation of novel mechanisms of resistance to single-agent and combination chemotherapy in ovarian cancer

    … and to the PARP inhibitors olaparib and rucaparib, but not to veliparib or AZD2461, correlating with increased ABCB1/P-glycoprotein-expression and Pglycoprotein efflux activity in both A2780pacR and A2780olapR cells. Bacterial membranes expressing P-glycoprotein confirmed active efflux of …

    dundee Repository record for Characterisation of novel mechanisms of resistance to single-agent and combination chemotherapy in ovarian cancer (opens in a new tab) Download PDF for Characterisation of novel mechanisms of resistance to single-agent and combination chemotherapy in ovarian cancer (opens in a new tab)

  4. Characterising Drug Resistance in the Colorectal Cancer Cell Line RKO

    … Irinotecan, Oxaliplatin, Miyabeacin, I-BET, JQ1, Rucaparib and Olaparib in a cell viability assay, also using MTT. Verapamil was added in combination with the last five of the compounds mentioned. The doubling time of RKO was 14.5 ± 0.4 hrs, RKOr5-FU was 18.0 ± 1.6 hrs, RKOrIRINO was 24.0 ± 4.7 …

    kent Download PDF for Characterising Drug Resistance in the Colorectal Cancer Cell Line RKO (opens in a new tab)

  5. Στοχευμένες θεραπευτικές προσεγγίσεις των PARP Inhibitors στον καρκίνο ωοθηκών / Targeted therapeutic approaches of PARP inhibitors in ovarian cancer

    … που αφορούν έξι κύριους αναστολείς (olaparib, rucaparib, niraparib, veliparib, talazoparib, pamiparib) με έμφαση στην αποτελεσματικότητα και την ασφάλειά τους. ΜΕΘΟΔΟΛΟΓΙΑ Πραγματοποιήθηκε ηλεκτρονική αναζήτηση στις βάσεις δεδομένων MEDLINE (μέσω του PubMed) και Scopus (μέσω της Elsevier). Το …

    athens Repository record for Στοχευμένες θεραπευτικές προσεγγίσεις των PARP Inhibitors στον καρκίνο ωοθηκών / Targeted therapeutic approaches of PARP inhibitors in ovarian cancer (opens in a new tab)

  6. Evaluación del potencial fotoquímico y fotobiológico de los inhibidores de la poli (ADP-ribosa) polimerasa

    … de los cinco de la tercera y última generación (rucaparib, talazoparib, niraparib, olaparib y veliparib), identificando así tres de ellos como posibles agentes fotosensibilizantes: rucaparib, talazoparib y niraparib, cuyo estudio se describe en profundidad en los capítulos 4, 5 y 6 de la tesis. …

    upv Repository record for Evaluación del potencial fotoquímico y fotobiológico de los inhibidores de la poli (ADP-ribosa) polimerasa (opens in a new tab)

  7. ATM-deficient cancer cells and targeted therapies

    … cell lines are sensitive to the PARP inhibitor Rucaparib as well as the ATR inhibitor VE-821. Using both lung and colorectal cancer cells, I also show that olaparib induces DNA damage and that olaparib causes an accumulation of G2 phase cells in ATM-deficient cells. Since olaparib is set to …

    calgary Repository record for ATM-deficient cancer cells and targeted therapies (opens in a new tab)

  8. A Tailored Viro-Immunotherapy Combination Approach for the Treatment of BRCA1/2 Mutated Breast and Ovarian Cancers

    … MDA-MB-231 breast cancer cells to the PARPi, rucaparib. Complementary work exploring the shuttling of miRNAs into small extracellular vesicles, or EVs, has also shown that we can take advantage of the EV packaging facilities in infected cells, inducing the packaging of miRNAs over-expressed by …

    ottawa-retro Repository record for A Tailored Viro-Immunotherapy Combination Approach for the Treatment of BRCA1/2 Mutated Breast and Ovarian Cancers (opens in a new tab)

  9. Investigating mechanisms of acquired drug resistance in Triple Negative Breast Cancer

    … showed that the PARP inhibitors, olaparib and rucaparib, and the chemotherapeutic agent, doxorubicin, may be ineffective as second treatment strategies for chemo-refractory TNBC, whilst inhibitors targeting CHK2, RAD51 recombinase and PLK1 may be effective. Analysis of the TNBC cell lines exome …

    kent Download PDF for Investigating mechanisms of acquired drug resistance in Triple Negative Breast Cancer (opens in a new tab)

  10. Δεδομένα φαρμακοεπαγρύπνησης των PARP inhibitors στον καρκίνο ωοθηκών και μαστού / Pharmacovigilance data of PARP inhibitors in ovarian and breast cancer

    … για τους PARP αναστολείς Οlaparib, Niraparib, Rucaparib και Talazoparib που ήδη έχουν πάρει έγκριση από τις ρυθμιστικές αρχές άλλα και για αυτούς που βρίσκονται σε πειραματικό στάδιο όπως οι Veliparib, Saruparib, Pamiparib και Fluzoparib. Για κάθε φάρμακο μελετήθηκαν οι κλινικές μελέτες φάσης …

    athens Repository record for Δεδομένα φαρμακοεπαγρύπνησης των PARP inhibitors στον καρκίνο ωοθηκών και μαστού / Pharmacovigilance data of PARP inhibitors in ovarian and breast cancer (opens in a new tab)

  11. Characterisation of Colorectal Cancer Cell Line LoVo and Drug-Adapted LoVo Cell Lines

    … irinotecan, oxaliplatin, miyabeacin, I-BET, JQ1, rucaparib, Olaparib, and verapamil) in comparison to the parental LoVo cell line. This assay can show which drugs may be effective in combination, or which may be useful if resistance shows to a certain drug, and conclusions may also be able to be …

    kent Download PDF for Characterisation of Colorectal Cancer Cell Line LoVo and Drug-Adapted LoVo Cell Lines (opens in a new tab)

  12. Υπολογισμός hrd score σε γυναικολογικούς καρκίνους

    … in the United States; olaparib, niraparib, rucaparib, and talazoparib. The purpose of this thesis is the investigation of the most appropriate algorithm for HRD score calculation as well as to determine the cut off of patients with a higher probability of PARP inhibitors treatment response. …

    greece Repository record for Υπολογισμός hrd score σε γυναικολογικούς καρκίνους (opens in a new tab)

  13. CHARACTERIZATION OF MOLECULAR AND GENETIC DETERMINANTS OF POLY (ADP-RIBOSE) POLYMERASE INHIBITOR SENSITIVITY IN OVARIAN CANCER

    … lead to the decreased expression of BRCA1 in rucaparib-resistant breast cancer cells and enhanced sensitivity to rucaparib. Collectively, these results suggest that FOXM1 plays an important role in the adaptive response induced by olaparib and that FOXM1 inhibition by thiostrepton contributes …

    ku Repository record for CHARACTERIZATION OF MOLECULAR AND GENETIC DETERMINANTS OF POLY (ADP-RIBOSE) POLYMERASE INHIBITOR SENSITIVITY IN OVARIAN CANCER (opens in a new tab)

  14. Expression von Steroidrezeptoren und anderen Hormonrezeptoren in Ovarialkarzinomen

    … sich im Zulassungsprozess, wie beispielsweise Rucaparib. Für viele Patientinnen gibt es jedoch weiterhin noch keine Optionen einer zielgerichteten, personalisierten Therapie. Daher war es das Ziel der vorliegenden Dissertation eine Gruppe von Rezeptoren auf ihre Expression hin zu untersuchen, …

    lmu-germany Repository record for Expression von Steroidrezeptoren und anderen Hormonrezeptoren in Ovarialkarzinomen (opens in a new tab)